Articles

A Study of Multiple Causes of Death in RA
F.A. Pinheiro, D.C. Souza, E.I. Sato 2217

The Risk of TB in Patients with RA Treated with TNF-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies

Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with RA in Remission: A CORRONA and NinJa Collaborative Cohort Study
K. Yoshida, H. Radner, M.D. Mjaavatten, et al 2238

RA: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden
A.B. Pedersen, A. Mor, F. Mehnert, R.W. Thomsen, S.P. Johnsen, M. Nørgaard 2247

Concomitant MTX Protects Against TKA in Patients with RA Treated with TNF Inhibitors
S. Asai, N. Takahashi, K. Funahashi, et al 2255

Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in RA: A Systematic Review and Metaanalysis
C. Vidal, T. Barnetche, J. Morel, B. Combe, C. Daïen 2261

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol
M.E. Clowse, D.C. Wolf, F. Förger, et al 2270

Clinical and Radiographic Outcomes in Patients Diagnosed with Early RA in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study
G. Haugeberg, P. Bayesen, K. Helgetveit, A. Proven 2279

Safety and Efficacy of Belimumab to Treat SLE in Academic Clinical Practices

A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset SLE
M.F. Silva, M.P. Ferriani, M.T. Terreri, et al 2296

Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset SLE
Y. Yang, S. Kumar, L.S. Lim, E.D. Silverman, D.M. Levy 2304

Nighttime Blood Pressure Patterns and Subclinical Atherosclerosis in Women with SLE

Lack of Interferon and Proinflammatory Cytokine/chemokines in Serologically Active Clinically Quiescent SLE

Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort
L. Sáez-Comet, C.P. Simeón-Aznar, M. Pérez-Conesa, et al, and the RESCLE Investigators 2327

Patient’s Global Assessment as an Outcome Measure for PsA in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
E. Lubrano, F.M. Perrotta, W.J. Parsons, A. Marchesoni 2332

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
A.V. Heinonen, K.J. Aaltosen, J.T. Joensuu, et al 2339

Effects of Aerobic Training in Patients with Ankylosing Spondylitis

Fatigue in Ankylosing Spondylitis and Nonradiographic AxSpA: Analysis from a Longitudinal Observation Cohort
M. Bedaiwi, I. Sari, A. Thavaneswaran, R. Ayeaest, N. Haroon, R.D. Inman 2354

Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in AxSpA
M. Dougados, E. Wood, L. Gossec, A. Dubanchet, I. Logeat, D. van der Heijde 2361

Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls
S. van Genderen, A. Boonen, D. van der Heijde, et al 2369

TNF-α Inhibition in Ankylosing Spondylitis and Nonradiographic AxSpA: Treatment Response, Drug Survival, and Patient Outcome

Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the USA
K. Raimundo, A.M. Farr, G. Kim, G. Duna 2383